Kaposi's sarcoma: A model of both malignancy and chronic inflammation

Panminerva Medica

Volumn 49, Issue 3, 2007, Pages 119-138

  Douglas, J L ^a   Gustin, J K ^a   Dezube, B J ^b,d   Pantanowitz, L ^c   Moses, A V ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Apoptosis; Herpesvirus 8, human; Immune factors; Inflammation; Neoplasms; Sarcoma, Kaposi; Virus latency

Indexed keywords

GENETICS; HUMAN; INFLAMMATION; KAPOSI SARCOMA; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; VIROLOGY;

HUMANS; INFLAMMATION; SARCOMA, KAPOSI;

EID: 36348942822     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (186)

1. Casper C, Redman M, Huang ML, Pauk J, Lampinen TM, Hawes SE et al. HIV infection and human herpesvirus-8 oral shedding among men who have sex with men. J Acquir Immune Defic Syndr 2004;35:233-8.
2. Chatlynne LG, Ablashi, DV. Seroepidemiology of Kaposi's sarcoma-associated herpesvirus (KSHV). Semin Cancer Biol 1999;9:175-85.
3. Pantanowitz L, Dezube BJ. Advances in the pathobiology and treatment of Kaposi sarcoma. Curr Opin Oncol 2004;16:443-9.
4. Dezube BJ, Pantanowitz L, Aboulafia, DM. Management of AIDS-related Kaposi sarcoma: advances in target discovery and treatment. AIDS Read 2004;14:236-8, 243-4, 251-3.
5. Gill PS, Tsai YC, Rao AP, Spruck CH 3rd, Zheng T, Harrington WA Jr et al. Evidence for multiclonality in multicentric Kaposi's sarcoma. Proc Natl Acad Sci U S A 1998;95:8257-61.
6. Rabkin CS, Janz S, Lash A, Coleman AE, Musaba E, Liotta L et al. Monoclonal origin of multicentric Kaposi's sarcoma lesions. N Engl J Med 1997;336:988-93.
7. Nickoloff BJ. PECAM-1 (CD31) is expressed on proliferating endothelial cells, stromal spindle-shaped cells, and dermal dendrocytes in Kaposi's sarcoma. Arch Dermatol 1993;129:250-1.
8. Nickoloff BJ. The human progenitor cell antigen (CD34) is localized on endothelial cells, dermal dendritic cells, and perifollicular cells in formalin-fixed normal skin, and on proliferating endothelial cells and stromal spindle-shaped cells in Kaposi's sarcoma. Arch Dermatol 1991;127:523-9.
9. Uccini S, Ruco LP, Monardo F, Stoppacciaro A, Dejana E, La Parola IL et al. Co-expression of endothelial cell and macrophage antigens in Kaposi's sarcoma cells. J Pathol 1994;173:23-31.
10. Uccini S, Sirianni MC, Vincenzi L, Topino S, Stoppacciaro A, Lesnoni La Parola I et al. Kaposi's sarcoma cells express the macrophage-associated antigen mannose receptor and develop in peripheral blood cultures of Kaposi's sarcoma patients. Am J Pathol 1997;150:929-38.
11. Kaaya EE, Parravicini C, Ordonez C, Gendelman R, Berti E, Gallo RC et al. Heterogeneity of spindle cells in Kaposi's sarcoma: comparison of cells in lesions and in culture. J Acquir Immune Defic Syndr Hum Retroviral 1995;10:295-305.
12. Regezi JA, MacPhail LA, Daniels TE, DeSouza YG, Greenspan JS, Greenspan, D. Human immunodeficiency virus-associated oral Kaposi's sarcoma. A heterogeneous cell population dominated by spindle-shaped endothelial cells. Am J Pathol 1993;143:240-9.
13. Nickoloff BJ, Griffiths CE. Factor XIIIa-expressing dermal dendrocytes in AIDS-associated cutaneous Kaposi's sarcomas. Science 1989;243:1736-7.
14. Beckstead JH, Wood GS, Fletcher, V. Evidence for the origin of Kaposi's sarcoma from lymphatic endothelium. Am J Pathol 1985;119:294-300.
15. Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol 2002; 15:434-40.
16. Jussila, L, Valtola, R, Partanen, TA, Salven, P, Heikkila, P, Matikainen, MT et al. Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res 1998;58:1599-604.
17. Weninger W, Partanen TA, Breiteneder-Geleff S, Mayer C, Kowalski H, Mildner M et al. Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. Lab Invest 1999;79:243-51.
18. Xu H, Edwards JR, Espinosa O, Banerji S, Jackson DG, Athanasou NA. Expression of a lymphatic endothelial cell marker in benign and malignant vascular tumors. Hum Pathol 2004;35:857-61.
19. Nadimi H, Saatee S, Armin A, Toto PD. Expression of endothelial cell markers PAL-E and EN-4 and Ia-antigens in Kaposi's sarcoma. J Oral Pathol 1988;17:416-20.
20. Herndier B, Ganem D. The biology of Kaposi's sarcoma. Cancer Treat Res 2001;104:89-126.
21. Wang HW, Trotter MW, Lagos D, Bourboulia D, Henderson S, Makinen T et al. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet 2004;36:687-93.
22. Hong YK, Foreman K, Shin JW, Hirakawa S, Curry CL, Sage DR et al. Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nat Genet 2004;36:683-5.
23. Pyakurel P, Pak F, Mwakigonja AR, Kaaya E, Heiden T, Biberfeld P. Lymphatic and vascular origin of Kaposi's sarcoma spindle cells during tumor development. Int J Cancer 2006;119:1262-7.
24. Blasig C, Zietz C, Haar B, Neipel F, Esser S, Brockmeyer NH et al. Monocytes in Kaposi's sarcoma lesions are productively infected by human herpesvirus 8. J Virol 1997;71:7963-8.
25. Monini P, Colombini S, Sturzl M, Goletti D, Cafaro A, Sgadari C et al. Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma. Blood 1999;93:4044-58.
26. Pellet C, Kerob D, Dupuy A, Carmagnat MV, Mourah S, Podgorniak MP et al. Kaposi's sarcoma-associated herpesvirus viremia is associated with the progression of classic and endemic Kaposi's sarcoma. J Invest Dermatol 2006;126:621-7.
27. Miles SA, Rezai AR, Salazar-Gonzalez JF, Vander Meyden M, Stevens RH, Logan DM et al. AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc Natl Acad Sci U S A 1990;87:4068-72.
28. Delli Bovi P, Donti E, Knowles DM 2nd, Friedman-Kien A, Luciw PA, Dina D et al. Presence of chromosomal abnormalities and lack of AIDS retrovirus DNA sequences in AIDS-associated Kaposi's sarcoma. Cancer Res 1986;46:6333-8.
29. Dourmishev LA, Dourmishev AL, Palmeri D, Schwartz RA, Lukac DM. Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis. Microbiol Mol Biol Rev 2003;67:175-212, table of contents.
30. Ballestas ME, Chatis PA, Kaye KM. Efficient persistence of extra-chromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science 1999;284:641-4.
31. Lan K, Kuppers DA, Verma SC, Robertson ES. Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen inhibits lytic replication by targeting Rta: a potential mechanism for virus-mediated control of latency. J Virol 2004;78:6585-94.
32. Friborg J Jr, Kong W, Hottiger MO, Nabel GJ. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 1999;402:889-94.
33. Si H, Robertson ES. Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen induces chromosomal instability through inhibition of p53 function. J Virol 2006;80:697-709.
34. Radkov SA, Kellam P, Boshoff C. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med 2000;6:1121-7.
35. nd, Robertson ES. The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus transactivates the telomerase reverse transcriptase promoter. J Biol Chem 2001;276:22971-8.
36. Verma SC, Borah S, Robertson ES. Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus up-regulates transcription of human telomerase reverse transcriptase promoter through interaction with transcription factor Sp1. J Virol 2004;78:10348-59.
37. Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, Neipel F et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997;386:517-21.
38. Chaudhary PM, Jasmin A, Eby MT, Hood L. Modulation of the NF-kappa B pathway by virally encoded death effector domains-containing proteins. Oncogene 1999;18:5738-46.
39. Djerbi M, Screpanti V, Catrina AI, Bogen B, Biberfeld P, Grandien A. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med 1999;190:1025-32.
40. Li M, Lee H, Yoon DW, Albrecht JC, Fleckenstein B, Neipel F et al. Kaposi's sarcoma-associated herpesvirus encodes a functional cyclin. J Virol 1997;71:1984-91.
41. Kliche S, Nagel W, Kremmer E, Atzler C, Ege A, Knorr T et al. Signaling by human herpesvirus 8 kaposin A through direct membrane recruitment of cytohesin-1. Mol Cell 2001;7:833-43.
42. Arvanitakis L, Geras-Raaka E, Varma A, Gershengorn MC, Cesarman E. Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature 1997;385:347-50.
43. Couty JP, Gershengorn MC. Insights into the viral G protein-coupled receptor encoded by human herpesvirus type 8 (HHV-8). Biol Cell 2004;96:349-54.
44. Bais C, Santomasso B, Coso O, Arvanitakis L, Raaka EG, Gutkind JS et al. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 1998;391:86-9.
45. Sodhi A, Montaner S, Patel V, Zohar M, Bais C, Mesri EA et al. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res 2000; 60:4873-80.
46. Lee H, Guo J, Li M, Choi JK, DeMaria M, Rosenzweig M et al. Identification of an immunoreceptor tyrosine-based activation motif of K1 transforming protein of Kaposi's sarcoma-associated herpesvirus. Mol Cell Biol 1998;18:5219-28.
47. Lagunoff M, Majeti R, Weiss A, Ganem D. Deregulated signal transduction by the K1 gene product of Kaposi's sarcoma-associated herpesvirus. Proc Natl Acad Sci U S A 1999;96:5704-9.
48. Prakash O, Swamy OR, Peng X, Tang ZY, Li L, Larson JE et al. Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesis. Blood 2005;105:3987-94.
49. Wang S, Wang S, Maeng H, Young DP, Prakash O, Fayad LE et al. K1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-mediated apoptosis. Blood 2007;109:2174-82.
50. Wang L, Wakisaka N, Tomlinson CC, DeWire SM, Krall S, Pagano JS et al. The Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) K1 protein induces expression of angiogenic and invasion factors. Cancer Res 2004;64:2774-81.
51. Offermann MK. Kaposi sarcoma herpesvirus-encoded interferon regulator factors. Curr Top Microbiol Immunol 2007;312:185-209.
52. Shin YC, Nakamura H, Liang X, Feng P, Chang H, Kowalik TF et al. Inhibition of the ATM/p53 signal transduction pathway by Kaposi's sarcoma-associated herpesvirus interferon regulatory factor 1. J Virol 2006;80:2257-66.
53. Burysek L, Yeow WS, Lubyova B, Kellum M, Schafer SL, Huang YQ et al. Functional analysis of human herpesvirus 8-encoded viral interferon regulatory factor 1 and its association with cellular interferon regulatory factors and p300. J Virol 1999;73:7334-42.
54. Li M, Damania B, Alvarez X, Ogryzko V, Ozato K, Jung, JU. Inhibition of p300 histone acetyltransferase by viral interferon regulatory factor. Mol Cell Biol 2000;20:8254-63.
55. Nakamura H, Li M, Zarycki J, Jung JU. Inhibition of p53 tumor suppressor by viral interferon regulatory factor. J Virol 2001;75:7572-82.
56. Seo T, Park J, Lee D, Hwang SG, Choe J. Viral interferon regulatory factor 1 of Kaposi's sarcoma-associated herpesvirus binds to p53 and represses p53-dependent transcription and apoptosis. J Virol 2001;75:6193-8.
57. Seo T, Park J, Choe J. Kaposi's sarcoma-associated herpesvirus viral IFN regulatory factor 1 inhibits transforming growth factor-beta signaling. Cancer Res 2005;65:1738-47.
58. Lin R, Genin P, Mamane Y, Sgarbanti M, Battistini A, Harrington WJ Jr et al. HHV-8 encoded vIRF-1 represses the interferon antiviral response by blocking IRF-3 recruitment of the CBP/p300 coactivators. Oncogene 2001;20:800-11.
59. Lagos D, Trotter MW, Vart RJ, Wang HW, Matthews NC, Hansen A et al. Kaposi sarcoma herpesvirus-encoded vFLIP and vIRF1 regulate antigen presentation in lymphatic endothelial cells. Blood 2007;109:1550-8.
60. Burysek L, Yeow WS, Pitha PM. Unique properties of a second human herpesvirus 8-encoded interferon regulatory factor (vIRF-2). J Hum Virol 1999;2:19-32.
61. Fuld S, Cunningham C, Klucher K, Davison AJ, Blackbourn, DJ. Inhibition of interferon signaling by the Kaposi's sarcoma-associated herpesvirus full-length viral interferon regulatory factor 2 protein. J Virol 2006;80:3092-7.
62. Burysek L, Pitha PM. Latently expressed human herpesvirus 8-encoded interferon regulatory factor 2 inhibits double-stranded RNA-activated protein kinase. J Virol 2001;75:2345-52.
63. Rivas C, Thlick AE, Parravicini C, Moore PS, Chang Y. Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J Virol 2001;75:429-38.
64. Zhu FX, King SM, Smith EJ, Levy DE, Yuan Y. A Kaposi's sarcoma-associated herpesviral protein inhibits virus-mediated induction of type I interferon by blocking IRF-7 phosphorylation and nuclear accumulation. Proc Natl Acad Sci U S A 2002;99:5573-8.
65. Staudt MR, Dittmer DP. The Rta/Orf50 transactivator proteins of the gamma-herpesviridae. Curr Top Microbiol Immunol 2007;312:71-100.
66. Yu Y, Wang SE, Hayward GS. The KSHV immediate-early transcription factor RTA encodes ubiquitin E3 ligase activity that targets IRF7 for proteosome-mediated degradation. Immunity 2005;22:59-70.
67. Molden J, Chang Y, You Y, Moore PS, Goldsmith MA. A Kaposi's sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit. J Biol Chem 1997;272:19625-31.
68. Aoki Y, Jaffe ES, Chang Y, Jones K, Teruya-Feldstein J, Moore PS et al. Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood 1999;93:4034-43.
69. Chatterjee M, Osborne J, Bestetti G, Chang Y, Moore PS. Viral IL-6-induced cell proliferation and immune evasion of interferon activity. Science 2002;298:1432-5.
70. Mullick J, Bernet J, Singh AK, Lambris JD, Sahu A. Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) open reading frame 4 protein (kaposica) is a functional homolog of complement control proteins. J Virol 2003;77:3878-81.
71. Spiller OB, Blackbourn DJ, Mark L, Proctor DG, Blom AM. Functional activity of the complement regulator encoded by Kaposi's sarcoma-associated herpesvirus. J Biol Chem 2003;278:9283-9.
72. Spiller OB, Robinson M, O'Donnell E, Milligan S, Morgan BP, Davison AJ et al. Complement regulation by Kaposi's sarcoma-associated herpesvirus ORF4 protein. J Virol 2003;77:592-9.
73. Coscoy L, Ganem D. Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis. Proc Natl Acad Sci U S A 2000;97:8051-6.
74. Ishido S, Wang C, Lee BS, Cohen GB, Jung JU. Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins. J Virol 2000;74:5300-9.
75. Li Q, Means R, Lang S, Jung JU. Downregulation of gamma interferon receptor 1 by Kaposi's sarcoma-associated herpesvirus K3 and K5. J Virol 2007;81:2117-27.
76. Mansouri M, Douglas J, Rose PP, Gouveia K, Thomas G, Means RE et al. Kaposi sarcoma herpesvirus K5 removes CD31/PECAM from endothelial cells. Blood 2006;108:1932-40.
77. Bartee E, McCormack A, Fruh K. Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog 2006;2:e107.
78. Park J, Seo T, Hwang S, Lee D, Gwack Y, Choe J. The K-bZIP protein from Kaposi's sarcoma-associated herpesvirus interacts with p53 and represses its transcriptional activity. J Virol 2000;74:11977-82.
79. Wang HW, Sharp TV, Koumi A, Koentges G, Boshoff C. Characterization of an anti-apoptotic glycoprotein encoded by Kaposi's sarcoma-associated herpesvirus which resembles a spliced variant of human survivin. Embo J 2002;21:2602-15.
80. Feng, P, Scott, CW, Cho, NH, Nakamura, H, Chung, YH, Monteiro, MJ et al. Kaposi's sarcoma-associated herpesvirus K7 protein targets a ubiquitin-like/ubiquitin-associated domain-containing protein to promote protein degradation. Mol Cell Biol 2004;24:3938-48.
81. Sarid R, Sato T, Bohenzky RA, Russo JJ, Chang Y. Kaposi's sarcoma-associated herpesvirus encodes a functional bcl-2 homologue. Nat Med 1997;3:293-8.
82. Nicholas J. Human gammaherpesvirus cytokines and chemokine receptors. J Interferon Cytokine Res 2005;25:373-83.
83. Kledal TN, Rosenkilde MM, Coulin F, Simmons G, Johnsen AH, Alouani S et al. A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science 1997;277:1656-9.
84. Weber KS, Grone HJ, Rocken M, Klier C, Gu S, Wank R et al. Selective recruitment of Th2-type cells and evasion from a cytotoxic immune response mediated by viral macrophage inhibitory protein-II. Eur J Immunol 2001;31:2458-66.
85. Boshoff C, Endo Y, Collins PD, Takeuchi Y, Reeves JD, Schweickart VL et al. Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science 1997;278:290-4.
86. Stine JT, Wood C, Hill M, Epp A, Raport CJ, Schweickart VL et al. KSHV-encoded CC chemokine vMIP-III is a CCR4 agonist, stimulates angiogenesis, and selectively chemoattracts TH2 cells. Blood 2000;95:1151-7.
87. Liu C, Okruzhnov Y, Li H, Nicholas J. Human herpesvirus 8 (HHV-8)-encoded cytokines induce expression of and autocrine signaling by vascular endothelial growth factor (VEGF) in HHV-8-infected primary-effusion lymphoma cell lines and mediate VEGF-independent antiapoptotic effects. J Virol 2001;75:10933-40.
88. McCormick C, Ganem D. The kaposin B protein of KSHV activates the p38/MK2 pathway and stabilizes cytokine mRNAs. Science 2005;307:739-41.
89. Moses AV, Jarvis MA, Raggo C, Bell YC, Ruhl R, Luukkonen BG et al. Kaposi's sarcoma-associated herpes virus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells. J Virol 2002;76:8383-99.
90. Roth WK, Werner S, Schirren CG, Hofschneider PH. Depletion of PDGF from serum inhibits growth of AIDS-related and sporadic Kaposi's sarcoma cells in culture. Oncogene 1989;4:483-7.
91. Cornali E, Zietz C, Benelli R, Weninger W, Masiello L, Breier G et al. Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma. Am J Pathol 1996;149:1851-69.
92. Raggo C, Ruhl R, McAllister S, Koon H, Dezube BJ, Fruh K et al. Novel cellular genes essential for transformation of endothelial cells by Kaposi's sarcoma-associated herpesvirus. Cancer Res 2005;65:5084-95.
93. Stahl N, Boulton TG, Farruggella T, Ip NY, Davis S, Witthuhn BA et al. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science 1994;263:92-5.
94. Lutticken C, Wegenka UM, Yuan J, Buschmann J, Schindler C, Ziemiecki A et al. Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science 1994;263:89-92.
95. Fukada T, Hibi M, Yamanaka Y, Takahashi-Tezuka M, Fujitani Y, Yamaguchi T et al. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity 1996;5:449-60.
96. Oh H, Fujio Y, Kunisada K, Hirota H, Matsui H, Kishimoto T et al. Activation of phosphatidylinositol 3-kinase through glycoprotein 130 induces protein kinase B and p70 S6 kinase phosphorylation in cardiac myocytes. J Biol Chem 1998;273:9703-10.
97. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996;271:736-41.
98. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Casfleman's disease. Blood 1989;74:1360-7.
99. Blankaert D, Simonart T, Van Vooren JP, Parent D, Liesnard C, Farber CM et al. Constitutive release of metalloproteinase-9 (92-kd type IV collagenase) by Kaposi's sarcoma cells. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:203-9.
100. Impola U, Cuccuru MA, Masala MV, Jeskanen L, Cottoni F, Saarialho-Kere U. Preliminary communication: matrix metalloproteinases in Kaposi's sarcoma. Br J Dermatol 2003;149:905-7.
101. Meade-Tollin LC, Way D, Witte MH. Expression of multiple matrix metalloproteinases and urokinase type plasminogen activator in cultured Kaposi sarcoma cells. Acta Histochem 1999;101:305-16.
102. Ye FC, Blackbourn DJ, Mengel M, Xie JP, Qian LW, Greene W et al. Kaposi's sarcoma-associated herpesvirus promotes angiogenesis by inducing angiopoietin-2 expression via AP-1 and Ets1. J Virol 2007;81:3980-91.
103. Carroll PA, Kenerson HL, Yeung RS, Lagunoff M. Latent Kaposi's sarcoma-associated herpesvirus infection of endothelial cells activates hypoxia-induced factors. J Virol 2006;80:10802-12.
104. Takeda N, Maemura K, Imai Y, Harada T, Kawanami D, Nojiri T et al. Endothelial PAS domain protein 1 gene promotes angiogenesis through the transactivation of both vascular endothelial growth factor and its receptor, Flt-1. Circ Res 2004;95:146-53.
105. Sarid R, Flore O, Bohenzky RA, Chang Y, Moore PS. Transcription mapping of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1). J Virol 1998;72:1005-12.
106. Pearce M, Matsumura S, Wilson AC. Transcripts encoding K12, v-FLIP, v-cyclin, and the microRNA cluster of Kaposi's sarcoma-associated herpesvirus originate from a common promoter. J Virol 2005;79:14457-64.
107. Samols MA, Hu J, Skalsky RL, Renne R. Cloning and identification of a microRNA cluster within the latency-associated region of Kaposi's sarcoma-associated herpesvirus. J Virol 2005;79:9301-5.
108. Flore O, Rafii S, Ely S, O'Leary JJ, Hyjek EM, Cesarman E. Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus. Nature 1998;394:588-92.
109. Sun Q, Zachariah S, Chaudhary PM. The human herpes virus 8-encoded viral FLICE-inhibitory protein induces cellular transformation via NF-kappaB activation. J Biol Chem 2003;278:52437-45.
110. Chugh P, Matta H, Schamus S, Zachariah S, Kumar A, Richardson JA et al. Constitutive NF-kappaB activation, normal Fas-induced apoptosis, and increased incidence of lymphoma in human herpes virus 8 K13 transgenic mice. Proc Natl Acad Sci U S A 2005;102:12885-90.
111. Keller SA, Schattner EJ, Cesarman E. Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 2000;96:2537-42.
112. Guasparri I, Keller SA, Cesarman E. KSHV vFLIP is essential for the survival of infected lymphoma cells. J Exp Med 2004;199:993-1003.
113. Field N, Low W, Daniels M, Howell S, Daviet L, Boshoff C et al. KSHV vFLIP binds to IKK-gamma to activate IKK. J Cell Sci 2003;116:3721-8.
114. Guasparri I, Wu H, Cesarman E. The KSHV oncoprotein vFLIP contains a TRAF-interacting motif and requires TRAF2 and TRAF3 for signalling. EMBO Rep 2006;7:114-9.
115. Matsushime H, Quelle DE, Shurtleff SA, Shibuya M, Sherr CJ, Kato JY. D-type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol 1994;14:2066-76.
116. Van Dross R, Browning PJ, Pelling JC. Do truncated cyclins contribute to aberrant cyclin expression in cancer? Cell Cycle 2006;5:472-7.
117. Davis MA, Sturzl MA, Blasig C, Schreier A, Guo HG, Reitz M et al. Expression of human herpesvirus 8-encoded cyclin D in Kaposi's sarcoma spindle cells. J Natl Cancer Inst 1997;89:1868-74.
118. Reed JA, Nador RG, Spaulding D, Tani Y, Cesarman E, Knowles, DM. Demonstration of Kaposi's sarcoma-associated herpes virus cyclin D homolog in cutaneous Kaposi's sarcoma by colorimetric in situ hybridization using a catalyzed signal amplification system. Blood 1998;91:3825-32.
119. Carbone A, Gloghini A, Bontempo D, Monini P, Tirelli U, Volpe R et al. Proliferation in HHV-8-positive primary effusion lymphomas is associated with expression of HHV-8 cyclin but independent of p27(kip1). Am J Pathol 2000;156:1209-15.
120. Chang Y, Moore PS, Talbot SJ, Boshoff CH, Zarkowska T, Godden K et al. Cyclin encoded by KS herpesvirus. Nature 1996;382:410.
121. Ellis M, Chew YP, Fallis L, Freddersdorf S, Boshoff C, Weiss RA et al. Degradation of p27(Kip) cdk inhibitor triggered by Kaposi's sarcoma virus cyclin-cdk6 complex. Embo J 1999;18:644-53.
122. Godden-Kent D, Talbot SJ, Boshoff C, Chang Y, Moore P, Weiss RA et al. The cyclin encoded by Kaposi's sarcoma-associated herpesvirus stimulates cdk6 to phosphorylate the retinoblastoma protein and histone H1. J Virol 1997;71:4193-8.
123. Mann DJ, Child ES, Swanton C, Laman H, Jones N. Modulation of p27(Kip1) levels by the cyclin encoded by Kaposi's sarcoma-associated herpesvirus. Embo J 1999;18:654-63.
124. Laman H, Coverley D, Krude T, Laskey R, Jones N. Viral cyclin-cyclin-dependent kinase 6 complexes initiate nuclear DNA replication. Mol Cell Biol 2001;21:624-35.
125. Swanton C, Mann DJ, Fleckenstein B, Neipel F, Peters G, Jones N. Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature 1997;390:184-7.
126. Verschuren EW, Hodgson JG, Gray JW, Kogan S, Jones N, Evan GI. The role of p53 in suppression of KSHV cyclin-induced lymphoma-genesis. Cancer Res 2004;64:581-9.
127. Verschuren EW, Klefstrom J, Evan GI, Jones N. The oncogenic potential of Kaposi's sarcoma-associated herpesvirus cyclin is exposed by p53 loss in vitro and in vivo. Cancer Cell 2002;2:229-41.
128. Zhong W, Wang H, Herndier B, Ganem D. Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma. Proc Natl Acad Sci U S A 1996;93:6641-6.
129. Staskus KA, Zhong W, Gebhard K, Herndier B, Wang H, Renne R et al. Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol 1997;71:715-9.
130. Muralidhar S, Pumfery AM, Hassani M, Sadaie MR, Kishishita M, Brady JN et al. Identification of kaposin (open reading frame K12) as a human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) transforming gene. J Virol 1998;72:4980-8.
131. Mocroft A, Youle M, Gazzard B, Morcinek J, Halai R, Phillips AN. Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. Aids 1996;10:1101-5.
132. Glesby MJ, Hoover DR, Weng S, Graham NM, Phair JP, Detels R et al. Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. J Infect Dis 1996;173:1477-80.
133. Martin DF, Kuppermann BD, Wolitz RA, Palestine AG, Li H, Robinson CA. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 1999;340:1063-70.
134. Bais C, Van Geelen A, Eroles P, Mutlu A, Chiozzini C, Dias S et al. Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/ KDR. Cancer Cell 2003;3:131-43.
135. Yang TY, Chen SC, Leach MW, Manfra D, Homey B, Wiekowski M et al. Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma. J Exp Med 2000;191:445-54.
136. Montaner S, Sodhi A, Molinolo A, Bugge TH, Sawai ET, He Y et al. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 2003;3:23-36.
137. Guo HG, Sadowska M, Reid W, Tschachler E, Hayward G, Reitz M. Kaposi's sarcoma-like tumors in a human herpesvirus 8 ORF74 transgenic mouse. J Virol 2003;77:2631-9.
138. Jensen KK, Manfra DJ, Grisotto MG, Martin AP, Vassileva G, Kelley K et al. The human herpes virus 8-encoded chemokine receptor is required for angioproliferation in a murine model of Kaposi's sarcoma. J Immunol 2005;174:3686-94.
139. Glaunsinger B, Ganem, D. Lytic KSHV infection inhibits host gene expression by accelerating global mRNA turnover. Mol Cell 2004;13:713-23.
140. Sodhi A, Montaner S, Gutkind JS. Does dysregulated expression of a deregulated viral GPCR trigger Kaposi's sarcomagenesis? Faseb J 2004; 18:422-7.
141. Lee H, Veazey R, Williams K, Li M, Guo J, Neipel F et al. Deregulation of cell growth by the K1 gene of Kaposi's sarcoma-associated herpesvirus. Nat Med 1998;4:435-40.
142. Prakash O, Tang ZY, Peng X, Coleman R, Gill J, Farr G et al. Tumorigenesis and aberrant signaling in transgenic mice expressing the human herpesvirus-8 K1 gene. J Natl Cancer Inst 2002;94:926-35.
143. Damania B. Oncogenic gamma-herpesviruses: comparison of viral proteins involved in tumorigenesis. Nat Rev Microbiol 2004;2:656-68.
144. Lanier LL. Viral immunoreceptor tyrosine-based activation motif (ITAM)-mediated signaling in cell transformation and cancer. Trends Cell Biol 2006;16:388-90.
145. Lagunoff M, Lukac DM, Ganem D. Immunoreceptor tyrosine-based activation motif-dependent signaling by Kaposi's sarcoma-associated herpesvirus K1 protein: effects on lytic viral replication. J Virol 2001;75:5891-8.
146. Wang L, Dittmer DP, Tomlinson CC, Fakhari FD, Damania B. Immortalization of primary endothelial cells by the K1 protein of Kaposi's sarcoma-associated herpesvirus. Cancer Res 2006;66:3658-66.
147. Moore PS, Boshoff C, Weiss RA, Chang Y. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 1996;274:1739-44.
148. Gao SJ, Boshoff C, Jayachandra S, Weiss RA, Chang Y, Moore PS. KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway. Oncogene 1997;15:1979-85.
149. Li M, Lee H, Guo J, Neipel F, Fleckenstein B, Ozato K et al. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor. J Virol 1998;72:5433-40.
150. Jayachandra S, Low KG, Thlick AE, Yu J, Ling PD, Chang Y et al. Three unrelated viral transforming proteins (vIRF, EBNA2, and E1A) induce the MYC oncogene through the interferon-responsive PRF element by using different transcription coadaptors. Proc Natl Acad Sci U S A 1999;96:11566-71.
151. Koon HB, Pantanowitz L, Dezube BJ. Antiangiogenic therapy for Kaposi's sarcoma. In: Davis D, Herbst RS, Abbruzzese JL editors. Anti-angiogenic cancer therapy. Boca Raton, FL: CRC; 2007. p. 753-81.
152. Poole U, Yu Y, Kim PS, Zheng QZ, Pevsner J, Hayward GS. Altered patterns of cellular gene expression in dermal microvascular endothelial cells infected with Kaposi's sarcoma-associated herpesvirus. J Virol 2002;76:3395-420.
153. Cornelissen M, van der Kuyl AC, van den Burg R, Zorgdrager F, van Noesel CJ, Goudsmit J. Gene expression profile of AIDS-related Kaposi's sarcoma. BMC Cancer 2003;3:7.
154. McAllister SC, Hansen SG, Ruhl RA, Raggo CM, DeFilippis VR, Greenspan D et al. Kaposi sarcoma-associated herpesvirus (KSHV) induces heme oxygenase-1 expression and activity in KSHV-infected endothelial cells. Blood 2004;103:3465-73.
155. Lennartsson J, Ronnstrand L. The stem cell factor receptor/c-Kit as a drug target in cancer. Curr Cancer Drug Targets 2006;6:65-75.
156. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006;203:2201-13.
157. Lubyova B, Pitha, PM. Characterization of a novel human herpesvirus 8-encoded protein, vIRF-3, that shows homology to viral and cellular interferon regulatory factors. J Virol 2000;74:8194-201.
158. Lubyova B, Kellum MJ, Frisancho AJ, Pitha PM. Kaposi's sarcoma-associated herpesvirus-encoded vIRF-3 stimulates the transcriptional activity of cellular IRF-3 and IRF-7. J Biol Chem 2004;279:7643-54.
159. Dittmer DP. Transcription profile of Kaposi's sarcoma-associated herpesvirus in primary Kaposi's sarcoma lesions as determined by real-time PCR arrays. Cancer Res 2003;63:2010-5.
160. Kanno T, Sato Y, Sata T, Katano H. Expression of Kaposi's sarcoma-associated herpesvirus-encoded K10/10.1 protein in tissues and its interaction with poly(A)-binding protein. Virology 2006;352:100-9.
161. Parravicini C, Chandran B, Corbellino M, Berti E, Paulli M, Moore PS et al. Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Am J Pathol 2000;156:743-9.
162. Cunningham C, Barnard S, Blackbourn DJ, Davison AJ. Transcription mapping of human herpesvirus 8 genes encoding viral interferon regulatory factors. J Gen Virol 2003;84:1471-83.
163. Pozharskaya VP, Weakland LL, Zimring JC, Krug LT, Unger ER, Neisch A et al. Short duration of elevated vIRF-1 expression during lytic replication of human herpesvirus 8 limits its ability to block antiviral responses induced by alpha interferon in BCBL-1 cells. J Virol 2004;78:6621-35.
164. Coscoy L, Ganem D. A viral protein that selectively downregulates ICAM-1 and B7-2 and modulates T cell costimulation. J Clin Invest 2001;107:1599-606.
165. Ishido S, Choi JK, Lee BS, Wang C, DeMaria M, Johnson RP et al. Inhibition of natural killer cell-mediated cytotoxicity by Kaposi's sarcoma-associated herpesvirus K5 protein. Immunity 2000;13:365-74.
166. Sanchez DJ, Gumperz JE, Ganem D. Regulation of CD1d expression and function by a herpesvirus infection. J Clin Invest 2005;115:1369-78.
167. Gwack Y, Hwang S, Byun H, Lim C, Kim JW, Choi EJ et al. Kaposi's sarcoma-associated herpesvirus open reading frame 50 represses p53-induced transcriptional activity and apoptosis. J Virol 2001;75:6245-8.
168. Krishnan HH, Naranatt PP, Smith MS, Zeng L, Bloomer C, Chandran B. Concurrent expression of latent and a limited number of lytic genes with immune modulation and antiapoptotic function by Kaposi's sarcoma-associated herpesvirus early during infection of primary endothelial and fibroblast cells and subsequent decline of lytic gene expression. J Virol 2004;78:3601-20.
169. Tomescu C, Law WK, Kedes DH. Surface downregulation of major histocompatibility complex class I, PE-CAM, and ICAM-1 following de novo infection of endothelial cells with Kaposi's sarcoma-associated herpesvirus. J Virol 2003;77:9669-84.
170. Adang LA, Tomescu C, Law WK, Kedes DH. Intracellular Kaposi's sarcoma-associated herpesvirus load determines early loss of immune synapse components. J Virol 2007;81:5079-90.
171. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005;5:749-59.
172. Schwarz M, Murphy PM. Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor constitutively activates NF-kappa B and induces proinflammatory cytokine and chemokine production via a C-terminal signaling determinant. J Immunol 2001;167:505-13.
173. Pati S, Cavrois M, Guo HG, Foulke JS Jr, Kim J, Feldman RA et al. Activation of NF-kappaB by the human herpesvirus 8 chemokine receptor ORF74: evidence for a paracrine model of Kaposi's sarcoma pathogenesis. J Virol 2001;75:8660-73.
174. Sadler R, Wu L, Forghani B, Renne R, Zhong W, Herndier B, et al. A complex translational program generates multiple novel proteins from the latently expressed kaposin (K12) locus of Kaposi's sarcoma-associated herpesvirus. J Virol 1999;73:5722-30.
175. O'Byrne KJ, Dalgleish AG, Browning MJ, Steward WP, Harris AL. The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer 2000;36:151-69.
176. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006;25:9-34.
177. Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med 2005;9:267-85.
178. Cianfrocca M, Cooley TP, Lee JY, Rudek MA, Scadden DT, Ratner L et al. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol 2002;20:153-9.
179. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-44.
180. Qian LW, Xie J, Ye F, Gao SJ. Kaposi's Sarcoma-associated herpesvirus infection promotes invasion of primary human umbilical vein endothelial cells by inducing matrix metalloproteinases. J Virol 2007;81:7001-10.
181. Brown LF, Dezube BJ, Tognazzi K, Dvorak HF, Yancopoulos GD. Expression of Tie1, Tie2, and angiopoietins 1, 2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol 2000;156:2179-83.
182. Di Lorenzo G, Konstantinopoulos PA, Pantanowitz L, Di Trolio R, De Placido S, Dezube BJ. Management of AIDS-related Kaposi's sarcoma. Lancet Oncol 2007; 8:167-76.
183. Konstantinopoulos PA, Sullivan RJ, Karamouzis MV, Dezube BJ. Investigational agents for treatment of AIDS-related Kaposi's sarcoma. Expert Opin Investig Drugs 2007;16:495-504.
184. Ledergerber B, Telenti A, Egger M. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. Swiss HIV Cohort Study. BMJ 1999;319:23-4.
185. Koon HB, Bubley GJ, Pantanowitz L, Masiello D, Smith B, Crosby K et al. Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol 2005;23:982-9.
186. Dezube BJ, Krown SE, Lee JY, Bauer KS, Aboulafia DM. Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study. J Clin Oncol 2006;24:1389-94.